Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Food and Drug Administration has approved three vaccines for RSV — GSK's Arexvy, Moderna's mRESVIA and Pfizer's ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Though the vaccine’s sales rose consistently till 2022, it started witnessing sluggish sales from 2024. Sales of the vaccine ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The FDA’s decision came a day ahead of the previously announced ... the only one approved for immunizing infants is Pfizer’s PFE Abrysvo. Unlike Beyfortus and Enflonsia, which can be administered ...

The poster further noted that RSV was found in 4,715 infants aged younger than 1 year since the FDA approved Abrysvo for pregnant women (incidence rate, 0.41%).

Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) prefusion F ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

Abrysvo has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older, as well as individuals aged 18 to 59 years at increased ...